UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027413
Receipt number R000031414
Scientific Title Prospective analyses of immunne response to establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor
Date of disclosure of the study information 2017/05/22
Last modified on 2023/05/24 15:53:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective analyses of immunne response to establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor

Acronym

Prospective analyses of immunne response to establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor

Scientific Title

Prospective analyses of immunne response to establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor

Scientific Title:Acronym

Prospective analyses of immunne response to establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor

Region

Japan


Condition

Condition

Solid tumor

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor

Basic objectives2

Others

Basic objectives -Others

To investigate mechanism of anti-cancer immunotherapies resistance

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To establish of predictive biomarker of anti-cancer immunotherapies effect in solid tumor

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Histologically or cytologically confirmed diagnosis of solid tumor (aged 20 years or older)
2. Immune checkpoint inhibitors treatment are planned
3. Biopsy of tumor tissue is planned for diagnoses
4. Drawing 30mL peripheral blood is considered proper

Key exclusion criteria

None

Target sample size

400


Research contact person

Name of lead principal investigator

1st name Hiroyoshi
Middle name
Last name Nishikawa

Organization

National Cancer Center Hospital East

Division name

Division of Cancer Immunology

Zip code

277-8577

Address

6-5-1 kashiwanoha kashiwa chiba

TEL

0471331111

Email

hnishika@east.ncc.go.jp


Public contact

Name of contact person

1st name Shohei
Middle name
Last name Koyama

Organization

National Cancer Center Hospital East

Division name

Division of Cancer Immunology

Zip code

277-8577

Address

6-5-1 kashiwanoha kashiwa chiba

TEL

0471331111

Homepage URL


Email

esugiyam@east.ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Cancer Center Institutional Review Board

Address

6-5-1 kashiwanoha kashiwa chiba

Tel

0471331111

Email

irst@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

がん研究会 有明病院


Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2016 Year 12 Month 05 Day

Date of IRB

2016 Year 09 Month 09 Day

Anticipated trial start date

2016 Year 12 Month 05 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a prospective observational study


Management information

Registered date

2017 Year 05 Month 19 Day

Last modified on

2023 Year 05 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031414


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name